Figure 4. B cell lymphoma (Bcl)-2
and Bcl-XL mRNA expression after treatment of p38
mitogen-activated protein kinases (MAPK) inhibitor and nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB)
siRNA. SB203580 and NF-κB siRNA inhibited Bcl-2
and Bcl-XL mRNA expression at 8 h after
ischemia/reperfusion (I/R). *Statistically significant compared
to the I/R control: p<0.05. n=6 in each group. Bcl-2
and Bcl-XL mRNA expressions were given as mean±standard
deviation (SD)